Arsenite exposure is known to increase the risk of neurological disorders via alteration of dopamine content, but the detailed molecular mechanisms remain largely unknown. In this study, using both dopaminergic neurons of the PC-12 cell line and C57BL/6J mice as in vitro and in vivo models, our results demonstrated that 6 months of arsenite exposure via drinking water caused significant learning and memory impairment, anxiety-like behavior and alterations in conditioned avoidance and escape responses in male adult mice. We also were the first to reveal that the reduction in dopamine content induced by arsenite mainly resulted from deficits in dopaminergic neurotransmission in the synaptic cleft. The reversible N6-methyladenosine (m6A) modification is a novel epigenetic marker with broad roles in fundamental biological processes. We further evaluated the effect of arsenite on the m6A modification and tested if regulation of the m6A modification by demethylase fat mass and obesity-associated (FTO) could affect dopaminergic neurotransmission. Our data demonstrated for the first time that arsenite remarkably increased m6A modification, and FTO possessed the ability to alleviate the deficits in dopaminergic neurotransmission in response to arsenite exposure. Our findings not only provide valuable insight into the molecular neurotoxic pathogenesis of arsenite exposure, but are also the first evidence that regulation of FTO may be considered as a novel strategy for the prevention of arsenite-associated neurological disorders.
Arsenite is a ubiquitous environmental toxicant that may cause a significant threat to human health based on known or suspected toxicity (Carlin et al., 2016) . Humans are routinely exposed to arsenite via contaminated drinking water, food, cigarettes, industrial wastes, air, etc. (Hughes et al., 2011) . Among the various routes of arsenite exposure, drinking water is the main source of arsenite contamination worldwide . Chronic exposure to arsenite through drinking water has been revealed to enhance the incidence of many types of cancers, cardiovascular disease, impairments of respiratory and metabolic functions, and defective immune responses (Abdul et al., 2015; Gentry et al., 2014; Hong et al., 2014; Kuo et al., 2017) . All forms of arsenite, including inorganic and methylated arsenicals, can accumulate in many regions of the brain (Du et al., 2018) . Therefore, of particular concern is the link between arsenite exposure and neurodegenerative diseases (EscuderoLourdes, 2016) . In fact, people exposed to even low concentrations of arsenite are at risk of developing neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease (Chin-Chan et al., 2015; Gong and O'Bryant 2010; Tyler and Allan, 2014) .
The main manifestations of neurodegenerative disorders include significant learning and memory deficits, as well as behavioral and thinking impairments (Escudero-Lourdes, 2016) . Intriguingly, these neurotoxic effects of arsenite have been demonstrated in exposed populations and animal models. For instance, previous reports have revealed that chronic exposure to arsenite via drinking water is capable of impairing cognitive abilities in both children and adults (Rosado et al., 2007; Tyler and Allan 2014) . Some other evidence presented suggests that ingestion of arsenite alters a number of intelligence measures and induces learning deficits and mood disorders (Hamadani et al., 2011; Sen and Biswas 2012) . Additionally, particularly in brain tissue of animals, arsenite was found to induce hyperphosphorylation of the tau protein and overregulation of the amyloid precursor protein, impaired neurotransmitter synthesis and glutamate metabolism, thus leading to altered synaptic transmission (Escudero-Lourdes, 2016; Prakash et al., 2016) . However, to date, the detailed mechanisms underlying how arsenite induces neurological disorders remain largely unknown. Dopaminergic transmission is able to govern the complex behaviors of humans, such as cognition, learning, emotion, reward-seeking behavior, etc. (Perry et al., 2016; Schultz et al., 2017; Westbrook and Braver, 2016) . The deregulation of dopaminergic transmission has been implicated in a wide range of diseases, including neurodegenerative diseases (Rangel-Barajas et al., 2015) . Interestingly, previous investigations demonstrated the opposite effects on the levels of dopamine and the expression of dopamine receptor (DRD) in response to arsenite exposure Moreno Avila et al., 2016; Rodr ıguez et al., 2010; Srivastava et al., 2016) . Specifically, rats treated with 100 mg/l arsenite for 3 weeks exhibited a decrease in the content of dopamine and immuno-reactivity of tyrosine hydroxylase (TH) in the striatum , while chronic exposure to 50 mg/l arsenite for 1 year caused hypoactivity of animals with increased dopamine content and up-regulated dopamine receptor expression (Rodr ıguez et al., 2010) . These findings indicate that the dopamine alteration induced by arsenite may depend on the dose and duration of exposure, as well as the regions of the brain detected (Du et al., 2018; Kim et al., 2014; Rodr ıguez et al., 2010) . Nevertheless, to date, how arsenite induces the dopaminergic transmission deficit is still unknown.
N6-methyladenosine (m6A) is the most abundant internal modification on eukaryotic mRNA. However, the biological significance of m6A methylation modification remains largely unexplored (Yue et al., 2015) . Several studies suggest that the dynamic regulation of m6A modification may have a profound impact on regulation of target gene expression (Cao et al., 2016; Fu et al., 2014) . The m6A modification is catalyzed by the methyltransferase complex containing METTL3, METTL14, and WTAP (known as the "writers"), but this RNA methylation can also be demethylated by specific RNA demethylases (known as the "eraser") (Cao et al., 2016) . Actually, the critical breakthrough that revived the m6A function came from the discovery of RNA demethylase, fat mass and obesity-associated (FTO) (Lee et al., 2014) . The FTO finding implicated the dynamic and reversible feature of m6A modification and further established a positive link to human health (Cao et al., 2016; Fu et al., 2014; Lee et al., 2014) . More importantly, scholars have recently found that FTO is present in dopamine neurons, and they revealed a new role for FTO in controlling the neurotransmission of dopamine .
Therefore, in this study, we employed both the dopaminergic neurons of PC-12 cell line and an animal model to test whether arsenite induces a dopaminergic transmission deficit and if this pathological process can be regulated by the m6A demethylase, FTO. Our findings will not only provide valuable insight into the molecular neurotoxic pathogenesis of arsenite but also present the first evidence that regulation of FTO may be considered as a novel strategy for the prevention of arseniteassociated neurotoxicity.
MATERIALS AND METHODS

Chemicals and Reagents
Arsenite, purity ! 99.0%, was purchased from Xiya Chemical Co. Ltd. (Cat: H4525, Shandong, China). The antibody targeting FTO was from GeneTex Inc. (USA). The TH antibody was obtained from Novus Biologicals (USA) and the catecholamine-O-methyltransferase (COMT) antibody was purchased from Affinity Biosciences (USA). Antibodies targeting DRD1-DRD5, and dopamine transporter (DAT) and Cy3/FITC-conjugated secondary antibodies were from Bioss Biotechnology (Beijing, China). The m6A antibody was obtained from the Synaptic Systems antibody company, and the antibody for b-actin was from ABclonal Biotechnology (USA). Fetal bovine serum (FBS) was from Ausbian (Australia). Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco Life Technologies (Grand Island, New York). Lipofectamine 2000 reagent was obtained from Invitrogen (Carlsbad, California). The CCK-8 assay kit was obtained from Dojindo Laboratories (Shanghai, China). The FTO siRNA and FTO CRISPR activation plasmid were from Santa Cruz Biotechnology Inc., (California). The mRNA Purification Kit was from Sangon Biotechnology Co. Ltd. (Shanghai, China). The RNA isolation kit was purchased from KeyGen Biotechnology Inc. (Nanjing, China). The 4', 6-Diamidino-2-phenylindole dihydrochloride (DAPI) and Nissl-staining kit were obtained from the Beyotime Institute of Biotechnology (Jiangsu, China).
Animals and Arsenite Treatment
Healthy C57BL/6J male mice, aged 7 weeks, weighting 20-24 g, were obtained from the Experimental Animal Center of Chongqing Medical University (Animal certificate number: SCXK, Chongqing, 2012-0001). The animals were kept in standard laboratory polycarbonate cages in controlled ambient temperature at 23 C 6 1 C with relative humidity of 50% 6 10%, and a light-dark cycle of 12/12 h. The mice had free access to standardized pellet food and tap water. After 1-week of habituation, the animals were randomly divided into the following 4 groups: control group, 0.5 mg/l arsenite group, 5 mg/l arsenite group and 50 mg/l arsenite group (n ¼ 16 per group). The mice were exposed to arsenite via drinking water for 6 months. This study was conducted in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the China National Institute of Health, and the protocols were approved by the Institutional Animal Care and Use Committee of Chongqing Medical University. All treatments were performed under gentle care and all efforts were made to minimize suffering of the animals.
Behavioral Test Battery
Morris water maze. The Morris water maze was employed to evaluate the spatial learning and memory function of the mice (Chen et al., 2012) . In brief, after habituating to the water maze with a 60-s free swim in the pool without a platform, the video camera was mounted above the pool to record the swim path of each animal with the tracking system. The hidden platform test was conducted for 4 consecutive days with 4 trials per day. During the trial, the swim distance, escape latency and the speed of mice were all recorded. On the final trial of day 5, a 60-s probe test with the platform removed was measured in the animals. The time spent in the target quadrant and the numbers of cross platform for each animal were recorded.
Radial arm (8-arm) maze. The radial arm maze was employed to evaluate the work and reference memory ability of mice according to the procedures described previously in Kassa et al. (2015) . In each test session, the animals were left to explore the maze for 10 min, and each food well contained a single food pellet. During the trial, the animals were monitored by a video camera suspended above the maze. Latency, test time, total entries into the arms, number of reference memory error and number of working memory error were recorded. The feces and urine in the maze were gently removed and cleaned with ethanol before the introduction of the next mouse to minimize the effects of lingering olfactory cues.
Shuttle-box avoidance test. The conditioned avoidance and escape responses of mice were evaluated by using the shutter-box test as described previously. The shuttle box contained 2 compartments separated by an automatic door, one clear and the other dark. The floor of the dark compartment is made of stainlesssteel rods connected to a shock generator. Before the training trial, the animals were allowed to habituate the environment. In the learning session, a buzzer was delivered in the compartments for 20 s, if the animals still stayed in this compartment, they received a foot shock for 10 s at 0.8 mA, and the mice were tested 30 trials each day with a 60-s average intertrial interval. The retention test started on the fifth day after the learning session. During the test, the time of active avoidance, the number of active avoidance, the time of passive avoidance responses, and the number of passive avoidance responses were all measured.
Open field test.
The open-field test was conducted to test the locomotor activity and anxiety-like behavior according to the procedures as described previously in Chen et al. (2012) . Briefly, the animals were placed in the open field apparatus and tested for 5 min. Each animal was placed initially in the center of the box and in the same square facing the same direction. The activity of the mice was observed by a video camera mounted above the box. The total distance, number of defecations, number of central square entries, distance moved in the center, and central square duration were observed. The apparatus was carefully cleaned with ethanol before testing of each animal.
Measurement of Arsenite Concentration by Using Atomic Fluorescence Spectroscopy
The concentration of arsenite was detected by atomic fluorescence spectrometry. In brief, the sample was fully homogenized by physiological saline, and subsequently, the 0.5 ml homogenate was digested with 5 ml digestion solution (perchloric acid:-nitrate, 1:9) in Teflon digestion tank (Sineo Microwave Chemistry Technology, Shanghai, China). The temperature was kept at approximately 180 C on the electronic temperature control plate (Ehc-1, Sineo Microwave Chemistry Technology, Shanghai, China). After colorless transparent and close dry, the sample was cooled to the room temperature, and then 0.5 ml 100 g/l thiourea ascorbic acid was added. Hydrochloric acid was used to adjust the solution volume to 5.0 ml, and the concentration of arsenite was determined by the atomic fluorescence photometer (AFS-230E, Haiguang, Beijing, China).
Measurement of Dopamine Content by Using High-Performance Liquid Chromatography
The content of dopamine was detected by high-performance liquid chromatography (HPLC) (1260 Infinity Agilent Technologies, Wilmington, Delaware). Briefly, after the samples were lysed with 0.6 M perchloric acid and 0.50 mM Na 2 EDTA, the supernatants were collected by centrifuging the sample at 4 C for 15 min at 14 000 rpm. The sample was thawed at low temperature before testing, and then an equal volume of perchloric acid precipitant, composed of 1.2 M K 2 HPO 4 and 2 mM Na 2 EDTA, was added. A dopamine standard reserve liquid of 0.1 mg/ml (National Institution for Food and Drug Control, Beijing, China) was made and stored at 4 C. Before analysis, samples and standard products were required to be filtered by 0.45 lm filter membranes. The chromatographic column was the Eclipse XDB-C18 column (4.6 Â 250 mm, 5 lm)(Agilent, USA); the mobile phase (pH 3.8) was 13% methanol containing 0.5 mM Na 2 EDTA, 50 mM citric acid, 0.5 mM 1-heptanesulfonic acid sodium salt, 5 mM triethylamine and 50 mM sodium acetate. The flow rate was 1.0 ml/min, the injection volume was 10 ll, and the excitation and emission wavelengths were 280 and 330 nm, respectively.
Transmission Electron Microscopy and Synapse Analysis
The ultrastructural changes of the synapse ultrastructure were observed by transmission electron microscopy as described previously in Yang et al. (2017) . Briefly, the animals were sacrificed and the cerebral cortices were excised and cut into 1 mm and dehydrated in alcohol. After the sections were stained with cresyl violet for 10 min, they were rinsed with tap water to remove excess stain, dehydrated by absolute ethanol, cleared in xylene, and mounted.
Western Blot Analysis
Western blot was performed according to procedures as described previously in Chen et al. (2016) . Briefly, protein samples were denatured, subjected to electrophoresis by sodium dodecyl sulfate polyacrylamide gel electrophoresis, followed by transferring to polyvinylidene difluoride membrane. The membrane was blocked with nonfat milk and incubated with primary antibodies against FTO (1:500), TH (1:1000), DAT (1:1000), COMT (1:700), DRD1 (1:400), DRD2 (1:400), DRD3 (1:400), DRD4 (1:400), DRD5 (1:500), and b-actin (1:50 000) overnight at 4 C. After incubation of the membranes with secondary antibodies for 1 h at room temperature, the blots were visualized by enhanced chemiluminescence reagents with a Molecular Imager Gel Doc XR System (Bio-Rad, USA). The intensity of the bands was analyzed by Quantity One software (Bio-Rad).
Immunofluorescence Assay An immunofluorescence assay was performed according to the protocols described previously in Chen et al. (2016) . Briefly, the fixed tissues/cells-containing slides were washed with phosphate-buffered saline followed by incubation of blocking solution for 1 h. The slices were then incubated with the primary anti-m6A (1:1000), anti-FTO (1:200), and anti-TH (1:300) antibodies at 4 C overnight. On the next day, the tissue was incubated with the Cy3/FITC-conjugated secondary antibody (1:10 000) at room temperature for 1 h. Subsequently, the slices were stained with DAPI and observed under a fluorescence microscope (Olympus, IX53, Tokyo, Japan).
Dot Blot Assay
The levels of m6A modification were determined by dot blot assay as described previously in Xiang et al. (2017) . The isolated RNA was purified by using the mRNA Purification Kit following the manufacturer's instructions. At least 20 lg of purified RNA was denatured, and the serially diluted mRNA was incubated at 95 C to disrupt secondary structures in a heat block for 3 min.
mRNA was then transferred to the Hybond-Nþ membrane in a UV Crosslinker (Analytik Jena, Germany) twice using the Autocrosslink mode (1200 lJ for 50 s). Following blocking in the buffer, the membrane was incubated with anti-m6A antibody (1:500) overnight at 4 C. On the next day, the membrane was rinsed and incubated with the secondary antibody for 1 h at room temperature. The blots were visualized by enhanced chemiluminescence Western Blotting Substrate in the dark with a Molecular Imager Gel Doc XR System (Bio-Rad).
Cell Culture
The PC-12 Adh (ATCC CRL-1721.1 TM ) cell line was generously provided by Laboratory of Stem Cells and Tissue Engineering, Chongqing Medical University, China. Cells were maintained in high-glucose DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 lg/ml streptomycin. Cells were grown in 25 cm 2 culture flask in an incubator supplied with 5% CO 2 at 37 C, and passaged approximately every 2-4 days.
Cell Viability Assay
Cell viability was assessed by using a CCK-8 assay (Chen et al., 2016) . In brief, cells were seeded in 96-well plates at a density of 1 Â 10 4
, and subsequently incubated with designed concentrations of arsenite for 24 h. Thereafter, 100 ll of CCK-8 mixture solution (contained 10 ll CCK-8 and 90 ll free DMEM) was added to each well and incubated for an additional 4 h at 37 C in the dark. Absorbance at a wavelength of 570 nm was measured by a microplate spectrophotometer (BioTek, Doraville, Georgia).
FTO siRNA and CRISPR Activation Plasmid Treatment Cells were seeded in 6-well plates at a density of 1 Â 10 5 cells/ well for siRNA or CRISPR activation plasmid transfection. FTO siRNA, FTO CRISPR activation plasmid and negative controls were mixed with Lipofectamine 2000 according to the manufacturer's instructions. The transfection reagent mixture was then added into each well with free DMEM supplemented with FBS and incubated for another 5 h. After transfection, cells were used for the designed experiments.
Statistical Analysis
All experiments were performed independently at least 3 times. 
RESULTS
Effects of Chronic Arsenite Exposure on Body Weight and Water Consumption
Animal weight was registered 3 times a week, while water consumption was determined daily. As we showed in Supplementary Figure 1 , no significant change in body weight was observed after chronic exposure to different doses of arsenite (0.5, 5, and 50 mg/l) for 6 months. Arsenite treatment of arsenite did not alter water consumption of mice (data not shown). Moreover, no differences between control and exposed mice were found for general behavior throughout the duration of the experiments.
Effects of Chronic Arsenite Exposure on Neurobehavioral Functions
Previous studies have demonstrated that chronic exposure to arsenite via drinking water can cause cognitive impairments, learning deficits, and mood disorders in both animals and humans (Escudero-Lourdes, 2016; Tyler and Allan, 2014) . However, the potential effects of arsenite on neurobehavioral function in our system were unknown. Thus, after arsenite treatment, we first tested the spatial learning and memory function of mice by using the classic Morris water maze. Our data revealed that, during the training trials, all the animals from the 4 groups showed a remarkable decrease in the time needed to locate the platform ( Figure 1B) . Moreover, the escape latency of the arsenite-exposed mice showed significant differences on the days 3 and 4 compared with that of control mice ( Figure 1B) . Interestingly, we observed that the swim distances of both the 5 and 50 mg/l arsenite-treated groups were longer than those of controls on days 3 and 4, while only the high-dose group showed a longer swim distance on day 2 ( Figure 1A ). The swim speed of mice did not reach any statistical significance among the 4 groups ( Figure 1C ), indicating the motor abilities of the mice may not be affected by arsenite. Surprisingly, on the probe trial day (fifth day of the test), our results found that, the moderate and high-dose group showed the less time spent in the target quadrant ( Figure 1D ), but the number of platform crossings in all arsenite-treated groups was significantly lower than that in the controls ( Figure 1E ). Representative track maps of each group are shown in Figure 1F . These results together suggest that exposure to arsenite for a chronic period may cause spatial learning and memory impairments. Arsenite exposure impairs spatial learning and memory function in Morris water maze. After exposed to 0.5, 5, and 50 mg/l arsenite for 6 months, the spatial learning and memory ability of mice was evaluated by using Morris water maze. Animals were submitted to acquisition of an invisible platform for 4 consecutive days with 4 trials per day. During the trial, (A) Swim distance, (B) Escape latency, and (C) Speed of swim were recorded. One day after finishing the place navigation task, the platform was removed, and the (D) Time spend in target quadrant, (E) Number of cross platform was measured. Representative track maps of each group in Morris water maze were showed in (F). Data were expressed as mean 6 SD (n ¼ 6), and analyzed by using 1-way or repeated ANOVA analysis. *p < .05, compared with control group.
Second, to detect the effects of arsenite on work and reference memory function, we further employed the radial-arm (8-arm) maze. Our results observed that the latency of 0.5, 5, and 50 mg/l arsenite treated groups were all significantly enhanced in comparison with that in the controls (Figure 2A) . Total entries into the arm of 5 and 50 mg/l treated mice were significantly higher than those of controls ( Figure 2B ), but only the test time of the high-dose group was longer than that of the control group ( Figure 2C ). Importantly, we found that, after arsenite exposure, the number of reference memory errors in the high-dose and moderate groups were remarkably enhanced ( Figure 2D ). Moreover, all arsenite-treated groups showed a significant increase in the number of working memory errors when compared with the control group ( Figure 2E ).
Representative track maps of each group in the radial-arm maze are shown in Figure 2F . These findings indicate that, chronic arsenite exposure can cause deficits in the working and reference memories.
Next, we investigated the effects of arsenite on conditioned avoidance and escape responses by using the shutter-box test. When compared with control mice, the 0.5, 5, and 50 mg/ l arsenite-treated mice exhibited significant increases in the active avoidance and passive avoidance times (Figs. 3A and 3C ), whereas the number of active avoidance responses was sharply decreased by arsenite exposure ( Figure 3B ). As shown in Figure 3D , both the moderate and high-dose group showed a higher number of passive avoidance responses than the control group. These observations indicate that chronic arsenite Figure 2 . Arsenite exposure impairs work and reference memory function in radial-arm maze. Mice were treated with 0.5, 5, and 50 mg/l arsenite for 6 months and neurotoxic effects of arsenite on work and reference memory function were determined by radial-arm (8-arm) maze. The latency (A), total entries into the arm (B), test time (C), number of reference memory error (D), number of working memory error (E) were all recorded during the trials. Representative track maps of each group in radial-arm maze were showed in (F). Data were expressed as mean 6 SD (n ¼ 6). Statistical analysis was performed by 1-way ANOVA or Kruskal-Wallis test. *p < .05, compared with control group. exposure affects conditioned avoidance and escape responses in mice.
To further detect whether arsenite affects the locomotor activity and anxiety-like behavior, the open-field test was performed. Our data observed that, the number of defecations of mice was increased in the 5 and 50 mg/l arsenite-treated groups compared with that in the controls ( Figure 3F) . Moreover, the central square duration and distance moved in Figure 3 . Arsenic exposure affects conditioned avoidance and escape responses, locomotor activity, and anxiety-like behavior. After treating of mice with 0.5, 5, and 50 mg/l arsenite for 6 months, the conditioned avoidance and escape responses were detected by shutter-box test. During the trial, time of active avoidance (A), number of active avoidance (B), time of passive avoidance (C) and number of passive avoidance (D) were all recorded. To evaluate the locomotor activity and anxiety-like behavior of mice, the open-field test was conducted, and the total distance (E), defecation of mice (F), number of central square entry (G), distance moved in center (H), and central square duration (I) were recorded. Representative track maps of each group in the open-field test were also showed in (J). Data were expressed as mean 6 SD (n ¼ 6). Statistical analysis was performed by 1-way ANOVA test. *p < .05, compared with control group. the center were both reduced by arsenite exposure (Figs. 3H and  3I) . However, surprisingly, we did not find any alteration in the total distance or the number of central square entries (Figs. 3E and 3G) . Representative track maps of each group in the open field test are shown in Figure 3J . These findings suggest that chronic arsenite exposure may not cause hyperactivity or hypoactivity in animals, but this chronic treatment may be able to trigger anxiety-like behavior.
Effects of Chronic Arsenite Exposure on Arsenite and Dopamine Concentrations in the Cerebral Cortices of Mice
The cerebral cortex is the largest region of the brain and plays a key role in cognition, learning and memory functions etc. Moreover, previous studies have demonstrated that the cerebral cortex is also the main target organ of arsenite (Prakash et al., 2016; Zhang et al., 2016) . Therefore, in this study, we confirmed the notion that the concentrations of arsenite were significantly enhanced in the group treated with the high dose of arsenite compared with those in the control group ( Figure 4A ). Since the deficits in the neurobehavioral functions may result from the changes of the main neurotransmitter dopamine (Westbrook and Braver, 2016) and the alteration of dopamine is usually caused by the impairments of dopaminergic transmission (Kosillo et al., 2016) , we performed HPLC assay to test the levels of dopamine in the cerebral cortex. Our data found that the content of dopamine was significantly reduced by chronic arsenite exposure ( Figure 4B ).
Reduction in Dopamine in the Cerebral Cortex Induced by Arsenite Resulted From a Dopaminergic Transmission Deficit
Based on our results showing that dopamine is sharply reduced by arsenite, we further investigated whether arsenite-induced histopathological injury in the cerebral cortex, as well as the ultrastructural changes to synapse transmission. Nissl staining revealed that the number of Nissl bodies in the arsenite-treated mice was sharply decreased, and the bodies were blurred at the edges and weakly stained ( Figure 5B ). Transmission electron microscopy revealed that revealed that the mean and maximal postsynaptic density (PSD) thickness of the arsenite-treated groups were much higher than those of controls (Figs. 5C and  5D ). However, there were no significant differences in the width of the synaptic clefts, the lengths of the active zone, or the general morphology between arsenite-treated mice and controls (Figs. 5A, 5C, and 5D).
Next, to further verify if arsenite induces the impairments of dopaminergic transmission, we detected the protein expression of key regulators in dopamine synthesis, release, transport, decomposition and the receptors on the postsynaptic membrane. Our results found that the expression of TH, DAT, COMT, and the dopamine receptors (DRD1, DRD2, DRD4, and DRD5) was significantly decreased by arsenite in a dose-dependent manner (Figs. 6A-D) . Surprisingly, the changes in DRD3 expression did not reach statistical significance (Figs. 6C and 6D ). These results together indicate that chronic exposure to arsenite is capable of inducing a dopaminergic transmission deficit, thus leading to decreased dopamine content.
Dopaminergic Transmission Deficit Induced by Arsenite Could Be
Regulated by the m6A Demethylase FTO The m6A demethylase FTO is present in dopamine neurons and has been demonstrated to control dopaminergic neurotransmission . Thus, we further tested whether the arsenite-induced impairment of dopaminergic transmission could be regulated by FTO. By using immunofluorescence and dot blotting assay, we revealed that exposure to arsenite was able to elevate the levels of m6A modification both in vivo and in vitro (see in Supplementary Figure 2) . Moreover, this induction of the m6A modification might be associated with decreased protein expression of FTO (Figs. 7A and 7B) , indicating that the balance of m6A modification homeostasis is disrupted by the reduced demethylation ability. Next, we confirmed that the m6A demethylase FTO was present in dopamine neurons of mice, and more importantly, we found that arsenite caused decreased TH expression (marker for labeling dopaminergic neurons) and decreased FTO-TH co-localization when compared with those in controls ( Figure 7C ). To further verify these findings, by using cultured PC12 cells as an in vitro model, our results observed that 24 h of exposure of cells to various doses of arsenite caused decreased cell viability in a dose-dependent manner, and the optimal concentrations, 0.5, 1.5, and 2.5 lM were chosen for the following experiments ( Figure 8A ). We observed that the expression of dopaminergic neurotransmissionrelated key proteins, TH, DAT and COMT, as well as the content of dopamine were significantly decreased in response to Figure 4 . Arsenite exposure leads to increased arsenite concentration and decreased dopamine content in the cerebral cortices of mice. After exposed to 0.5, 5, and 50 mg/l arsenite for 6 months, the cerebral cortices of mice were collected and the concentrations of arsenite and dopamine were determined by using HPLC assay. The levels of arsenite in the cerebral cortices were showed in (A). The effects of arsenite on the concentrations of dopamine in the cerebral cortices of mice were showed in (B). Data were expressed as mean 6 SD (n ¼ 3). Statistical analysis was performed by 1-way ANOVA test. *p< .05, compared with control group. arsenite exposure (Figs. 8B-D) . Moreover, the level of FTO protein expression was sharply decreased by treatment of cells with arsenite (Figs. 8E-G) . These results were consistent with those observed in the animals. Interestingly, by using FTO siRNA and a CRISPR activation plasmid, we observed that the reduction in FTO expression induced by arsenite could be regulated by its specific siRNA and CRISPR activation plasmid (Figs. 9A-D) . Importantly, we found that the decreased expression of TH, DAT, and COMT was partially reversed by the CRISPR activation plasmid but exacerbated by FTO siRNA (Figs. 9E-H) . We also detected the effects of FTO on m6A level in response to arsenite expoure by using FTO siRNA and CRISPR activation plasmid (Supplementary Figure 3 and Figure 4 ). These findings together suggest that the dopaminergic transmission deficit induced by arsenite can be regulated by the m6A demethylase FTO.
DISCUSSION
Epidemiologic studies have shown that chronic exposure to arsenite is associated with an increased risk of developing neurodegenerative disorders (Carlin et al., 2016; Chin-Chan et al., 2015; Escudero-Lourdes, 2016; Tyler and Allan, 2014) . However, the molecular mechanisms underlying how arsenite causes the neurotoxic effects in the brain remain largely unknown. In this study, we used both in vivo and in vitro models to investigate the Figure 5 . Effects of arsenite exposure on brain general morphology, synaptic changes and Nissl bodies in mice. Mice were treated with 0.5, 5, and 50 mg/l arsenite for 6 months, and the brain tissues of mice were collected immediately under general anesthesia. A, No significant difference was observed on general morphology of brain among 4 groups. B, Representative images of Nissl staining showed the Nissl bodies of arsenite-treated mice were sharply decreased and the bodies also became blurred at the edges and pale stained. Scale bar ¼ 50 lm (n ¼ 3). C, Representative images in the transmission electron microscopy were showed. The arrows showed the typical synapse. Scale bar ¼ 1 nm (n ¼ 3). D, Quantitative results of transmission electron microscopy on the thickness of PSD, the width of synaptic cleft and the length of active zone (n ¼ 24). Data were expressed as mean 6 SD. Statistical analysis was performed by 1-way ANOVA test. *p < .05, compared with control group. role of dopaminergic neurotransmission in arsenite-induced neurobehavioral function deficits. Our results demonstrated that learning and memory impairments, anxiety-like behavior, and alterations in conditioned avoidance and escape responses were positively linked to chronic arsenite treatment via drinking water. Intriguingly, we also revealed for the first time that the functional neurobehavioral changes induced by arsenite resulted from dopaminergic neurotransmission deficits, which were regulated by the m6A demethylase FTO. Our data will provide new insights into the possible link between neurodegenerative disorders with dopaminergic neurotransmission deficits and imbalanced m6A modification.
Arsenicosis is a serious public health issue in China mainly caused by contaminated coal, tea, and drinking water (Sun, 2004) . However, the impact on human health has been underestimated and under-evaluated. Moreover, previous investigations focused primarily on the carcinogenicity of arsenite (Farooqi, 2015) . To our knowledge, the present study is the first to show noncancer-related neurotoxic effects of environmentally relevant levels of arsenite both in vivo and in vitro. Although the maximum allowable concentration of arsenite in the drinking water is limited at 0.01 mg/l in China, the doses of arsenite are up to almost 4.44 mg/l in some arsenitecontaminated areas (He and Charlet, 2013; Rodr ıguez-Lado et al., 2013; Wang et al., 2007) . In the heavily polluted industrial area, the levels of arsenite in the ground water are even higher than 5 mg/l (He and Charlet, 2013; Laskar et al., 2015) . The animal-tohuman uncertainty factor (usually ranging from 10 to 100) is typically used in noncancer risk assessments when available data are insufficient to support the application of chemical-and species-specific extrapolation factors (Borgonovo 2017) . Therefore, in this study, healthy adult C57BL/6J mice were exposed to 0.5, 5, and 50 mg/l arsenite for 6 months to simulate the environmental exposure of humans as much as possible. Furthermore, the doses of arsenite used in this study have already been tested in previous studies evaluating the toxic effects of arsenite (Bardullas et al., 2009; Gao et al., 2013) .
Neurobehavioral dysfunction can be considered as a marker for neurodegenerative disease. Moreover, the range of neurobehavioral functions affected by neurotoxicants is extremely wide, and for this reason, scholars typically use sets or batteries of neurobehavioral tests (Urbach et al., 2010) . Thus, in this study, by using the neurobehavioral test batteries, our data showed that chronic arsenite exposure not only caused learning and memory impairments but also led to deficits in conditioned avoidance, escape responses and anxiety-like behavior in the animal model. These results were consistent with previous studies conducted in rats that revealed that arsenite exposure (!50 mg/l) caused spatial learning and memory impairment (Jiang et al., 2014; Luo et al., 2009; Wu et al., 2006) . Moreover, investigations also revealed that 8 weeks of sub-chronic arsenite exposure (10 mg/l) could enhance depression-like behaviors in the mouse model, which was similar with our results observed in the open field test (Chang et al., 2015) . However, we demonstrated that, arsenite was able to induce alterations in conditioned avoidance and the escape response, as well as the working and reference memory deficits. These findings together imply that subtle neurobehavioral function deficits caused by prolonged arsenite exposure can progress to severe effects (such as neurodegenerative disease), and early detection may allow remedial action to be taken before neurobehavioral dysfunction progresses to irreversible brain damage.
Arsenite is known to alter the content of the neurotransmitter, dopamine. Moreover, the extent of arsenite-induced neurobehavioral dysfunctions may be correlated with the changes of dopamine Rodr ıguez et al., 2010; Zhang et al., 2013) . Here, we provided evidence that arsenite significantly decreased the dopamine content both in the cerebral cortex and in cultured PC12 cells. Additionally, we found the reduction of dopamine caused by arsenite mainly occurred through impaired Figure 7 . Arsenite exposure alters the expressions of FTO and its colocalization with TH in mice. After exposed to 0.5, 5, and 50 mg/l arsenite for 6 months, the cerebral cortices of mice were collected. A and B, Protein expressions of FTO after arsenite treatment were showed by using western blot analysis, and b-actin was served as loading control. C, Immunofluorescence assay showed the interaction and colocalization of FTO and TH in the cerebral cortex of mice. Scale bar was 50 and 100 lm in the far left panel. Data were expressed as mean 6 SD (n ¼ 3). Statistical analysis was performed by 1-way ANOVA test. *p < .05, compared with control group. neurotransmission in the synapse. Interestingly, the results of Kim et al. (2014) , were consistent with our study, demonstrating that after 3 weeks of 100 mg/l arsenite, TH expression and dopamine content were significantly decreased both in the striatum and the cerebral cortex of mice. In contrast, Rodr ıguez et al. (2010), revealed the completely opposite effects that treating albino rats with 50 mg/l arsenite for 1 year increased the levels of dopamine in the striatum. This discrepancy may be due to the differences between cells and animals, to the duration of exposure, or to the use of doses and different regions of the brain. Nevertheless, based on the observations of the expression of the key proteins in dopaminergic neurotransmission (TH, DAT, COMT, and DRDs), our findings are intriguing and suggest that arsenite decreases the content of dopamine in the cerebral cortex and cells via impaired dopaminergic neurotransmission.
As a significant epigenetic modification of nucleic acids, methylation can regulate gene expression, influence neurobehavioral of animals, and is closely related to the occurrence and development of neurodegenerative diseases (Satterlee et al., 2014) . The epigenetic regulatory mechanisms of DNA methylation on arsenite toxicity have been well established in the past decade (Alamdar et al., 2017; Du et al., 2018) . However, to date, RNA methylation, even though prevalent in many organisms, has not been demonstrated in the field of arsenite neurotoxicity. m6A is a ubiquitous modification in mRNA and other RNAs in diverse tissues. For decades, however, the exact functions of m6A modification were largely unknown (Cao et al., 2016) . FTO is primarily identified as an obesity-susceptibility gene, but a recent study discover that FTO is also a m6A demethylase, indicating that the m6A modification is reversible and dynamically regulated (Lee et al., 2014) . More importantly, FTO can be widely expressed in the brain and functions in the central nervous system to regulate postnatal growth (Gao et al., 2010) , brain foodcue responsivity (Karra et al., 2013) , and activity of dopaminergic circuitry . In this study, we revealed a new role of FTO in the regulation of dopaminergic neurotransmission. Intriguingly, our data now also extended the findings that targeting demethylase FTO to modulate m6A modification may protect against neurotoxic effects of arsenite. However, we have only tested mice and cells at this relatively limited time point, and without FTO knockout mice, we cannot fully understand the effects of FTO expression during the pathogenesis of neurodegenerative disorders induced by chronic arsenite exposure.
Recent study has revealed that the dynamic changes of m6A sites in transcripts including neurotransmitter secretion, synaptic vesicle exocytosis and signal release from synapse etc. (Weng et al., 2018) . Moreover, targeted m6A demethylation directed by demethylase is demonstrated as a potential mRNA regulatory mechanism in the neurons Nainar et al., 2016; Satterlee et al., 2014) . However, whether the effect of m6A modification is specific to dopamine-related mRNAs or not remains unsolved. To our knowledge, m6A may show the function on regulation of dopamine-related mRNAs via two major ways. One way is that, the dopamine-related mRNAs, such as TH and DRD receptors, have the m6A sites, the alterations of m6A modification on these dopamine-related mRNAs can directly change their expressions, thus affecting the levels of dopamine. The other way is that, the function of m6A modification on dopamine levels may be achieved by m6A modification demethylases that regulates the expression of dopamine-related genes, which may be capable to affect level of dopamine.
In summary, in this study, we demonstrated for the first time that, in response to arsenite exposure, the synthesis, transport, decomposition, and postsynaptic receptors of dopamine were disrupted, leading to deficits in dopaminergic neurotransmission and consequently causing neurobehavioral function impairments. Importantly, we also revealed that the deficits in dopaminergic neurotransmission could be regulated by the m6A demethylase FTO (schematic representation of the mechanism is shown in Figure 10 ). These findings may provide compelling evidence that new strategies can be developed for targeting the m6A demethylase FTO in the prevention or intervention against arsenite-related neurodegenerative diseases.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online. Figure 10 . Schematic diagram of the mechanism underlying how arsenite causes dopaminergic neurotransmission deficits. Schematic diagram of the mechanism underlying how arsenite causes dopaminergic neurotransmission deficits is shown. In response to arsenite exposure, the dopamine synthesis, transport, and decomposition as well as the postsynaptic receptors of dopamine are disrupted. These alterations can further lead to the deficits in the dopaminergic neurotransmission, reduction of dopamine, and consequently causing the neurobehavioral functions impairments. Importantly, the deficits of dopaminergic neurotransmission may be effectively regulated by m6A demethylase FTO.
